Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Confronting the opioid crisis with basic research in neuropharmacology.

Baumann MH, Pasternak GW, Negus SS.

Neuropharmacology. 2020 Jan 17:107972. doi: 10.1016/j.neuropharm.2020.107972. [Epub ahead of print]

PMID:
31958407
2.

Medications Development for Treatment of Opioid Use Disorder.

Townsend EA, Negus SS, Banks ML.

Cold Spring Harb Perspect Med. 2020 Jan 13. pii: a039263. doi: 10.1101/cshperspect.a039263. [Epub ahead of print]

PMID:
31932466
3.

Attenuated dopamine receptor signaling in nucleus accumbens core in a rat model of chemically-induced neuropathy.

Selley DE, Lazenka MF, Sim-Selley LJ, Secor McVoy JR, Potter DN, Chartoff EH, Carlezon WA Jr, Negus SS.

Neuropharmacology. 2020 Jan 6:107935. doi: 10.1016/j.neuropharm.2020.107935. [Epub ahead of print]

PMID:
31917153
4.

Comparison of chemotherapy effects on mechanical sensitivity and food-maintained operant responding in male and female rats.

Legakis LP, Diester CM, Townsend EA, Karim-Nejad L, Negus SS.

Behav Pharmacol. 2019 Dec 10. doi: 10.1097/FBP.0000000000000527. [Epub ahead of print]

PMID:
31833969
5.

Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone.

Schwienteck KL, Blake S, Bremer PT, Poklis JL, Townsend EA, Negus SS, Banks ML.

Drug Alcohol Depend. 2019 Nov 1;204:107501. doi: 10.1016/j.drugalcdep.2019.06.006. Epub 2019 Aug 24.

PMID:
31479865
6.

Experimental design and analysis for consideration of sex as a biological variable.

Diester CM, Banks ML, Neigh GN, Negus SS.

Neuropsychopharmacology. 2019 Dec;44(13):2159-2162. doi: 10.1038/s41386-019-0458-9. Epub 2019 Jul 5. No abstract available.

PMID:
31277076
7.

Interactions between pain states and opioid reward assessed with intracranial self-stimulation in rats.

Moerke MJ, Negus SS.

Neuropharmacology. 2019 Dec 1;160:107689. doi: 10.1016/j.neuropharm.2019.107689. Epub 2019 Jul 1. Review.

PMID:
31271771
8.

Pharmacological validation of a translational model of cocaine use disorder: Effects of d-amphetamine maintenance on choice between intravenous cocaine and a nondrug alternative in humans and rhesus monkeys.

Lile JA, Johnson AR, Banks ML, Hatton KW, Hays LR, Nicholson KL, Poklis JL, Rayapati AO, Rush CR, Stoops WW, Negus SS.

Exp Clin Psychopharmacol. 2019 Jul 1. doi: 10.1037/pha0000302. [Epub ahead of print]

PMID:
31259593
9.

Core Outcome Measures in Preclinical Assessment of Candidate Analgesics.

Negus SS.

Pharmacol Rev. 2019 Apr;71(2):225-266. doi: 10.1124/pr.118.017210. Review.

10.

Role of agonist efficacy in exposure-induced enhancement of mu opioid reward in rats.

Moerke MJ, Negus SS.

Neuropharmacology. 2019 Jun;151:180-188. doi: 10.1016/j.neuropharm.2019.03.020. Epub 2019 Mar 14.

PMID:
30880123
11.

Sex differences in opioid reinforcement under a fentanyl vs. food choice procedure in rats.

Townsend EA, Negus SS, Caine SB, Thomsen M, Banks ML.

Neuropsychopharmacology. 2019 Nov;44(12):2022-2029. doi: 10.1038/s41386-019-0356-1. Epub 2019 Feb 28.

PMID:
30818323
12.

Testing the 10 most wanted: a preclinical algorithm to screen candidate opioid use disorder medications.

Banks ML, Townsend EA, Negus SS.

Neuropsychopharmacology. 2019 May;44(6):1011-1012. doi: 10.1038/s41386-019-0336-5. Epub 2019 Feb 9. Review. No abstract available.

PMID:
30739125
13.

Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.

Schwienteck KL, Faunce KE, Rice KC, Obeng S, Zhang Y, Blough BE, Grim TW, Negus SS, Banks ML.

Neuropharmacology. 2019 May 15;150:200-209. doi: 10.1016/j.neuropharm.2019.01.020. Epub 2019 Jan 18.

PMID:
30660628
14.

Effects of the α2/α3-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam.

Moerke MJ, Li G, Golani LK, Cook J, Negus SS.

Behav Pharmacol. 2019 Aug;30(5):452-461. doi: 10.1097/FBP.0000000000000464.

PMID:
30640180
15.

Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.

Sakloth F, Leggett E, Moerke MJ, Townsend EA, Banks ML, Negus SS.

Exp Clin Psychopharmacol. 2019 Jun;27(3):215-226. doi: 10.1037/pha0000253. Epub 2019 Jan 10.

PMID:
30628811
16.

Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Negus SS, Moerke MJ.

Peptides. 2019 Feb;112:23-31. doi: 10.1016/j.peptides.2018.10.007. Epub 2018 Nov 1. Review.

PMID:
30391425
17.

Abuse Potential of Biased Mu Opioid Receptor Agonists.

Negus SS, Freeman KB.

Trends Pharmacol Sci. 2018 Nov;39(11):916-919. doi: 10.1016/j.tips.2018.08.007. Review.

PMID:
30343727
18.

Effects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats.

Suyama JA, Banks ML, Negus SS.

Psychopharmacology (Berl). 2019 Mar;236(3):1057-1066. doi: 10.1007/s00213-018-5029-y. Epub 2018 Sep 19.

PMID:
30232529
19.

Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys.

Schwienteck KL, Negus SS, Banks ML.

Behav Pharmacol. 2019 Jun;30(4):358-362. doi: 10.1097/FBP.0000000000000437.

PMID:
30212383
20.

Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142.

Moerke MJ, Ananthan S, Banks ML, Eltit JM, Freitas KC, Johnson AR, Saini SK, Steele TWE, Negus SS.

J Pharmacol Exp Ther. 2018 Nov;367(2):222-233. doi: 10.1124/jpet.118.250902. Epub 2018 Aug 27.

21.

Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats.

Johnson AR, Banks ML, Selley DE, Negus SS.

Neuropsychopharmacology. 2018 Jul;43(8):1753-1762. doi: 10.1038/s41386-018-0071-3. Epub 2018 Apr 19.

22.

Effects of N-Alkyl-4-Methylamphetamine Optical Isomers on Plasma Membrane Monoamine Transporters and Abuse-Related Behavior.

Battisti UM, Sitta R, Harris A, Sakloth F, Walther D, Ruchala I, Negus SS, Baumann MH, Glennon RA, Eltit JM.

ACS Chem Neurosci. 2018 Jul 18;9(7):1829-1839. doi: 10.1021/acschemneuro.8b00138. Epub 2018 May 14.

23.

Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats.

Sakloth F, Negus SS.

Exp Clin Psychopharmacol. 2018 Apr;26(2):195-204. doi: 10.1037/pha0000183. Epub 2018 Mar 12.

24.

Addressing the Opioid Crisis: The Importance of Choosing Translational Endpoints in Analgesic Drug Discovery.

Negus SS.

Trends Pharmacol Sci. 2018 Apr;39(4):327-330. doi: 10.1016/j.tips.2018.02.002. Epub 2018 Feb 28. Review.

25.

Lack of paclitaxel effects on intracranial self-stimulation in male and female rats: comparison to mechanical sensitivity.

Legakis LP, Bigbee JW, Negus SS.

Behav Pharmacol. 2018 Apr;29(2 and 3-Spec Issue):290-298. doi: 10.1097/FBP.0000000000000378.

26.

Repeated Morphine Produces Sensitization to Reward and Tolerance to Antiallodynia in Male and Female Rats with Chemotherapy-Induced Neuropathy.

Legakis LP, Negus SS.

J Pharmacol Exp Ther. 2018 Apr;365(1):9-19. doi: 10.1124/jpet.117.246215. Epub 2018 Jan 23.

27.

Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.

Cornelissen JC, Obeng S, Rice KC, Zhang Y, Negus SS, Banks ML.

J Pharmacol Exp Ther. 2018 Apr;365(1):37-47. doi: 10.1124/jpet.117.246439. Epub 2018 Jan 12.

28.

Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.

Lazenka ML, Moerke MJ, Townsend EA, Freeman KB, Carroll FI, Negus SS.

Psychopharmacology (Berl). 2018 Jan;235(1):203-213. doi: 10.1007/s00213-017-4758-7. Epub 2017 Oct 24.

29.

Maintenance on naltrexone+amphetamine decreases cocaine-vs.-food choice in male rhesus monkeys.

Moerke MJ, Banks ML, Cheng K, Rice KC, Negus SS.

Drug Alcohol Depend. 2017 Dec 1;181:85-93. doi: 10.1016/j.drugalcdep.2017.09.020. Epub 2017 Oct 13.

30.

Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats.

Townsend EA, Naylor JE, Negus SS, Edwards SR, Qureshi HN, McLendon HW, McCurdy CR, Kapanda CN, do Carmo JM, da Silva FS, Hall JE, Sufka KJ, Freeman KB.

Psychopharmacology (Berl). 2017 Sep;234(17):2597-2605. doi: 10.1007/s00213-017-4652-3. Epub 2017 May 31.

31.

Utility of Nonhuman Primates in Substance Use Disorders Research.

Banks ML, Czoty PW, Negus SS.

ILAR J. 2017 Dec 1;58(2):202-215. doi: 10.1093/ilar/ilx014. Review.

32.

N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability.

Solis E Jr, Partilla JS, Sakloth F, Ruchala I, Schwienteck KL, De Felice LJ, Eltit JM, Glennon RA, Negus SS, Baumann MH.

Neuropsychopharmacology. 2017 Sep;42(10):1950-1961. doi: 10.1038/npp.2017.98. Epub 2017 May 22.

33.

Effects of Acute and Chronic Treatments with Dopamine D2 and D3 Receptor Ligands on Cocaine versus Food Choice in Rats.

Thomsen M, Barrett AC, Butler P, Negus SS, Caine SB.

J Pharmacol Exp Ther. 2017 Jul;362(1):161-176. doi: 10.1124/jpet.117.241141. Epub 2017 May 4.

34.

Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model.

Grim TW, Morales AJ, Thomas BF, Wiley JL, Endres GW, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2017 Jul;362(1):210-218. doi: 10.1124/jpet.117.240192. Epub 2017 Apr 25.

35.
36.

Relief of Pain-Depressed Behavior in Rats by Activation of D1-Like Dopamine Receptors.

Lazenka MF, Freitas KC, Henck S, Negus SS.

J Pharmacol Exp Ther. 2017 Jul;362(1):14-23. doi: 10.1124/jpet.117.240796. Epub 2017 Apr 14.

37.

Role of d-amphetamine and d-methamphetamine as active metabolites of benzphetamine: Evidence from drug discrimination and pharmacokinetic studies in male rhesus monkeys.

Banks ML, Snyder RW, Fennell TR, Negus SS.

Pharmacol Biochem Behav. 2017 May;156:30-38. doi: 10.1016/j.pbb.2017.03.008. Epub 2017 Mar 31.

38.

Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents.

Altarifi AA, David B, Muchhala KH, Blough BE, Akbarali H, Negus SS.

J Psychopharmacol. 2017 Jun;31(6):730-739. doi: 10.1177/0269881116689257. Epub 2017 Feb 1.

39.

Oral modafinil facilitates intracranial self-stimulation in rats: comparison with methylphenidate.

Lazenka MF, Negus SS.

Behav Pharmacol. 2017 Jun;28(4):318-322. doi: 10.1097/FBP.0000000000000288.

40.

Insights from Preclinical Choice Models on Treating Drug Addiction.

Banks ML, Negus SS.

Trends Pharmacol Sci. 2017 Feb;38(2):181-194. doi: 10.1016/j.tips.2016.11.002. Epub 2016 Dec 2. Review.

41.
42.

Effects of 21-day d-amphetamine and risperidone treatment on cocaine vs food choice and extended-access cocaine intake in male rhesus monkeys.

Hutsell BA, Negus SS, Banks ML.

Drug Alcohol Depend. 2016 Nov 1;168:36-44. doi: 10.1016/j.drugalcdep.2016.08.637. Epub 2016 Sep 5.

43.

Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays.

Grim TW, Morales AJ, Gonek MM, Wiley JL, Thomas BF, Endres GW, Sim-Selley LJ, Selley DE, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2016 Nov;359(2):329-339. Epub 2016 Aug 17.

45.

Pharmacokinetic-Pharmacodynamic (PKPD) Analysis with Drug Discrimination.

Negus SS, Banks ML.

Curr Top Behav Neurosci. 2018;39:245-259. doi: 10.1007/7854_2016_36. Review.

46.

Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats.

Lazenka MF, Suyama JA, Bauer CT, Banks ML, Negus SS.

Pharmacol Biochem Behav. 2017 Jan;152:52-60. doi: 10.1016/j.pbb.2016.08.004. Epub 2016 Aug 24.

47.

Dissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters.

Solis E Jr, Suyama JA, Lazenka MF, DeFelice LJ, Negus SS, Blough BE, Banks ML.

Sci Rep. 2016 Aug 12;6:31385. doi: 10.1038/srep31385.

48.

Development of a translational model to screen medications for cocaine use disorder II: Choice between intravenous cocaine and money in humans.

Lile JA, Stoops WW, Rush CR, Negus SS, Glaser PE, Hatton KW, Hays LR.

Drug Alcohol Depend. 2016 Aug 1;165:111-9. doi: 10.1016/j.drugalcdep.2016.05.022. Epub 2016 May 28.

49.

Development of a translational model to screen medications for cocaine use disorder I: Choice between cocaine and food in rhesus monkeys.

Johnson AR, Banks ML, Blough BE, Lile JA, Nicholson KL, Negus SS.

Drug Alcohol Depend. 2016 Aug 1;165:103-10. doi: 10.1016/j.drugalcdep.2016.05.021. Epub 2016 May 28.

50.

Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys.

Smith DA, Negus SS, Poklis JL, Blough BE, Banks ML.

Addict Biol. 2017 Sep;22(5):1169-1178. doi: 10.1111/adb.12399. Epub 2016 Apr 6.

Supplemental Content

Loading ...
Support Center